Navigation Links
Repligen Licenses Patent Rights for Treatment of Bipolar Disorder
Date:3/31/2009

WALTHAM, Mass., March 31 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that it has exclusively licensed worldwide rights for the use of uridine in the treatment of patients with bipolar disorder from McLean Hospital. The use of uridine in the treatment of patients with bipolar disorder is currently the subject of a patent application and upon issue, the patent will remain in force until 2025 prior to any regulatory extensions. Under the terms of the license agreement, McLean will receive an upfront payment, development milestones and royalties upon successful commercialization of uridine for bipolar disorder. McLean Hospital is the largest psychiatric facility of Harvard Medical School and maintains the largest research program of any private, U.S. psychiatric hospital. Repligen is developing RG2417, an oral formulation of uridine, as a treatment for the depressive symptoms of bipolar disorder based on positive results of a previously reported Phase 2a clinical trial.

"Bipolar disorder affects more than two million adults in the United States," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. "Treatment of the symptoms of bipolar depression remains an area of significant unmet medical need, as current therapies are ineffective and result in numerous side effects. We look forward to completion of our ongoing proof-of-concept clinical trial which could provide a new approach to the treatment of bipolar depression."

Repligen is currently conducting a Phase 2b clinical trial of RG2417 designed to confirm and extend the positive results obtained in a Phase 2a clinical trial which demonstrated that RG2417 was well tolerated and resulted in a statistically significant improvement in the symptoms of bipolar depression over the six-week treatment period
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Repligen Announces ISO 9001:2000 Certification
2. Repligen Reports Second Quarter Fiscal Year 2009 Financial Results
3. Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder
4. Repligen Announces Conference Call of Second Quarter Fiscal Year 2009 Results Thursday, November 6th, 10:00 a.m. EST
5. Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors
6. Repligen Announces Share Repurchase Program
7. Repligen Announces Conference Call to Update Orencia(R) Lawsuit
8. Repligen Elects Earl Henry, M.D. to the Board of Directors
9. Repligen to Present at Upcoming Healthcare Conferences Wednesday, November 28th and Wednesday, December 5th
10. Repligen Reports Second Quarter Fiscal Year 2008 Financial Results
11. Recovery Audit Contractor HealthDataInsights Licenses Milliman Care Guidelines(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015 In the key developed markets, ... 2013 and is set to decrease through 2020 at a ... growth is expected up to 2017 at a 2.6% CAGR ... be owing to the surging penetration of fixed-dose combination drugs ... Plus, Valturna, Benicar HCT, and Tekamlo), a hike in the ...
(Date:3/26/2015)... In preparation for the 2016 United States ... Samir Becic, has issued “report cards” for potential ... fitness, as well as their promotion of health and ... Ted Cruz, who has officially announced his candidacy for ... who have shown interest in running for office. This ...
(Date:3/26/2015)... With the rapidly growing healthcare market and consumers ... its not just doctors who are now purchasing medical ... a piece of the action. HealthSource Chiropractic ®, the ... franchises purchased by people with no health backgrounds to ... Chiropractic is an exploding $12.7 billion dollar market with ...
(Date:3/26/2015)... 26, 2015 The beauty industry united ... a man who revolutionized the business of beauty education. ... Passage; founder of Pivot Point International, Inc. Passage’s wife ... of Leo. Held at the Art Institute of Chicago, ... of industry and media leaders and served as the ...
(Date:3/26/2015)... LinkToBanking, a Preferred Partner Network for the cannabis ... of the Board and Robert Casares as Vice-Chairman ... combined knowledge and experience in regulatory compliance and ... Casares will provide exceptional guidance on how to ... About Tom Fleming, Mr. Fleming, CAMS, has over ...
Breaking Medicine News(10 mins):Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 3Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 3Health News:HealthSource Chiropractic Franchise Expands National Footprint as Investors Buy In 2Health News:HealthSource Chiropractic Franchise Expands National Footprint as Investors Buy In 3Health News:#BeautyChangesLives Legacy Award Pays Tribute to Industry Icon Leo Passage 2Health News:#BeautyChangesLives Legacy Award Pays Tribute to Industry Icon Leo Passage 3Health News:Tom Fleming named Chairman of the Board and Robert Casares as Vice-Chairman of the Board of LinkToBanking 2Health News:Tom Fleming named Chairman of the Board and Robert Casares as Vice-Chairman of the Board of LinkToBanking 3
... team of researchers, including a number from the University of ... regions of the genome that contribute to the debilitating lung ... Their findings provide insight into the causes of the wide ... also points the way to new diagnostic markers and therapeutic ...
... , MONDAY, May 23 (HealthDay News) -- Cancer patients who ... greater sense of satisfaction about their treatment, a new study ... and accurate medical information built trust between patient and doctor. ... , the study analyzed 295 patients recently diagnosed with lymphoma, ...
... Monday, May 23, 2011 New findings out of Wake Forest ... in predicting early death in individuals with diabetes. ... Care . "People with diabetes are already at high risk ... W. Bowden, Ph.D., the director of the Center for Diabetes Research ...
... 22, 2011- Gothenburg, Sweden : The aldosterone antagonist ... new onset atrial fibrillation and flutter (AFF) in ... sub-analysis of the EMPHASIS-HF trial, presented at the ... Failure Association of the European Society of Cardiology ...
... Although chemotherapy is used to kill cancer cells, it ... such as bone marrow and blood cells, often limiting the ... Fred Hutchinson Cancer Research Center reported at today,s annual meeting ... Seattle that one possible approach to reduce this toxic effect ...
... , FRIDAY, May 20 (HealthDay News) -- The ... skin -- is significantly higher among overweight and obese kids, ... online in the Journal of Pediatrics , also found ... higher cholesterol levels, putting them at greater risk for heart ...
Cached Medicine News:Health News:Consortium identifies genome regions that could influence severity of cystic fibrosis 2Health News:Consortium identifies genome regions that could influence severity of cystic fibrosis 3Health News:Cancer Patients Benefit From Full Access to Medical Records 2Health News:Common test could help predict early death in diabetes, study shows 2Health News:Common test could help predict early death in diabetes, study shows 3Health News:EMPHASIS HF: Study shows epleronone to reduce atrial fibrillation 2Health News:EMPHASIS HF: Study shows epleronone to reduce atrial fibrillation 3Health News:Gene-modified stem cells help protect bone marrow from toxic side effects of chemotherapy 2Health News:Study Sees Link Between Psoriasis, Obesity in Kids 2
(Date:3/26/2015)... March 26, 2015  Oxis Biotech, Inc. ... International, Inc. [OTC: OXIS] and [Euronext Paris: ... exclusive option agreement with the University of ... by Dr. Xiang-Qun Xie , Associate ... Sciences, School of Pharmacy.  These patents/intellectual properties ...
(Date:3/26/2015)... -- IGI Laboratories, Inc. (NYSE MKT: IG), a ... company, today announced it has submitted its first abbreviated ... Drug Administration (FDA) of 2015, which brings the Company,s ... FDA to twenty-three. Jason Grenfell-Gardner , ... 2, 2015, we committed to file at least twenty ...
(Date:3/26/2015)... 26, 2015  CNBC profiled MJ Freeway , a ... a series "How I Did It," which features companies with ... Road" released yesterday, illustrates how two tech entrepreneurs from ... providers to the marijuana industry. ... Co-Founders Amy Poinsett and Jessica Billingsley used their ...
Breaking Medicine Technology:Oxis Biotech Executes Option Agreement to Certain Patents/Intellectual Properties Owned by the University of Pittsburgh 2Oxis Biotech Executes Option Agreement to Certain Patents/Intellectual Properties Owned by the University of Pittsburgh 3IGI Laboratories, Inc. Announces First ANDA Submission Of 2015 2MJ Freeway, Industry-Leading Software Solution for Cannabis Businesses, Featured in CNBC Special "How I Did It" 2
... ... Fibrillation Patients, CARLSBAD, Calif., Jan. 16 Ablation ... U.S.,Investigational Device Exemption (IDE) clinical trial for interventional,treatment of chronic atrial ... proceed with the pivotal phase of the,study is based on the ...
... Jan. 16 Cerimon,Pharmaceuticals, Inc., announced today it ... studies of its once-,daily topical diclofenac sodium patch ... studies, designated the "SUPPORT" (Stop Underlying Pain with ... assess the,efficacy and safety of Cerimon,s patch compared ...
Cached Medicine Technology:FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial 2FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial 3Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain 2Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain 3
... IDT six-slice imaging system provides advanced ... innovations to maximize performance and minimize ... to delivering optimal clinical results, Mx8000 ... multislice CT today and the foundation ...
... The Mx8000 IDT 10 offers premium-level performance with ... on any other systems in the 8- and ... 0.4 second rotation time, and submillimeter isotropic imaging ... interface and a simple upgrade to a 16-slice ...
... for everyday, 1/2-second high-speed scanning, Aquilion ... image resolution with longer, faster helical ... imaging., An improved X-ray tube and ... this supercharged CT scanner, giving it ...
... to facilitate disc removal, endplate preparation and ... fusion. The TLIF instruments are very low ... for which they were primarily designed, however ... in PLIF and ALIF. Disc rongeurs: used ...
Medicine Products: